CLINICAL TRIALS PROFILE FOR NEURACEQ
✉ Email this page to a colleague
All Clinical Trials for Neuraceq
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02831283 ↗ | Imaging Inflammation in Alzheimer's Disease | Enrolling by invitation | National Institute on Aging (NIA) | Phase 2 | 2016-06-01 | This study is being done to learn about inflammation and amyloid in Alzheimer's disease. A type of brain scan called a PET scan is used measure 1) inflammation and 2) abnormal accumulation of a the amount of a certain protein fragment called beta-amyloid (plaques) in the brain. These are thought to be involved in Alzheimer's disease. The investigators will also perform brain MRI and do tests to measure the participants' memory and thinking. |
| NCT02831283 ↗ | Imaging Inflammation in Alzheimer's Disease | Enrolling by invitation | William Charles Kreisl | Phase 2 | 2016-06-01 | This study is being done to learn about inflammation and amyloid in Alzheimer's disease. A type of brain scan called a PET scan is used measure 1) inflammation and 2) abnormal accumulation of a the amount of a certain protein fragment called beta-amyloid (plaques) in the brain. These are thought to be involved in Alzheimer's disease. The investigators will also perform brain MRI and do tests to measure the participants' memory and thinking. |
| NCT03119558 ↗ | PET/MRI Evaluation of Cardiac Amyloid | Completed | Stanford University | Early Phase 1 | 2016-05-26 | Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F-Florbetaben (Neuraceq®) that targets beta amyloid can also identify cardiac amyloid deposition. |
| NCT03744312 ↗ | Imaging Inflammation in Alzheimer's Disease With 11C-ER176 | Enrolling by invitation | William Charles Kreisl | Phase 1/Phase 2 | 2018-09-10 | This study is being done to learn about inflammation in the brain of those with Alzheimer's disease (AD). The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. Both patients (with either mild cognitive impairment (MCI) or Alzheimer's disease) and healthy controls (participants without memory complaints or impairment) will be included in this study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Neuraceq
Condition Name
Clinical Trial Locations for Neuraceq
Trials by Country
Clinical Trial Progress for Neuraceq
Clinical Trial Phase
Clinical Trial Sponsors for Neuraceq
Sponsor Name
